Core Insights - Sanofi has officially launched its insulin active pharmaceutical ingredient (API) project in Beijing, with a total investment of €1 billion, marking the first insulin API production base established by a multinational company in China [1][2] - The new facility will cover nearly 60,000 square meters and is expected to be fully operational by 2032, incorporating advanced production processes and quality systems that meet international standards [1] - The project aims to enhance the supply chain resilience and manufacturing network of Sanofi, while also contributing to the sustainable development strategy through green production measures [1][2] Investment and Strategic Importance - The investment underscores China's critical role as a strategic market for Sanofi and reflects the company's confidence in the long-term prospects of the Chinese economy and healthcare system [2] - The new base will collaborate with existing production sites in Beijing, Shenzhen, and Hangzhou to create a high-quality production network that efficiently meets the evolving medical needs of Chinese patients [2] Industry Context - Diabetes is a significant chronic disease globally, with approximately 828 million adults affected, highlighting the substantial demand for insulin and the importance of ensuring a stable and sustainable supply [1] - Sanofi's commitment to diabetes management and prevention aligns with China's "Healthy China 2030" vision, emphasizing collaboration with government, industry, and academic partners [2]